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Atherosclerotic Renovascular Hypertension 
: Lessons from Recent Clinical Studies
Atherosclerotic renovascular hypertension is a form of secondary hypertension 
due to renal artery stenosis. After the introduction of medical therapy such as 
with statins and angiotensin blocking agents, it has been considered a very 
slowly progressive disease. In the 1990s, surgical methods were compared to 
radiological intervention and showed no additional benefits. Recent clinical data 
also demonstrate that in cases of relatively stable atherosclerotic renovascular 
disease, medical therapy is as effective as other interventions with regard to 
patient outcomes. In this paper the recent clinical outcomes are reviewed. 
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Introduction
Atherosclerotic renal artery hypertension is reported in 
almost 7% of adults older than 65 years
1) and is associated with 
cardiovascular events, and may double risk of mortality
2). In 
the 1990s, radiological angioplasty began to replace surgical 
revascularization. Galaria et al. showed that percutaneous and 
open renal revascularization had equivalent long-term functional 
outcomes
3). Over time, the less-invasive procedure became more 
accessible. 
Most cases of atherosclerotic renovascular disease (ARVD) 
are located in the ostium, and are extensions of calcified aortic 
plaques
4). These lesions tend to return to their original shape with 
balloon angioplasty alone. Stent placement might also provide 
additional force to increase the rates of technical success
5) and to 
reduce the rate of restenosis at 6 months after the initial procedure
6). 
Intervention with stents has become a standard procedure; in 
patients with stenosis of the renal artery, placement of a stent is 
likely to be the initial form of treatment. However, there is limited 
evidence to support revascularization over medical therapy for 
patients with atherosclerotic renal artery stenosis
7, 8). 
Natural history
Retrospective studies previously reported that renal artery lesions 
might progress to severe stenosis and ultimately to renal artery 
occlusion
9). Michael et al. performed a prospective study that 
reported that the progression of renal artery disease was a frequent 
occurrence with an annual rate of progression of renal artery lesions 
reported to be 7%
10). However, at the time of these studies, statins 
were being used in fewer patients. A retrospective study of the 
effects of statins on the progression of ARVD has shown that the 
use of statins reduces the risk of progression and the development 
of ARVD
11). Another prospective population-based study reported 
that the progression to significant ARVD was observed in only 
4.0% during 8 years of follow-up (annualized rate, 0.5% per year), 
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and no case of ARVD progressed to occlusion
12). 
Dissociation between arterial patency and function
Hypertension and renal artery stenosis are not necessarily 
renovascular hypertension. Essential hypertension and clinically 
silent renal artery stenosis often coexist, and essential hypertension 
also coexists with renovascular hypertension
13). This is why blood 
pressure control does not always improve after stenting. 
Renal injury distal to an atherosclerotic renovascular obstruction 
is due to multiple intrinsic factors producing parenchymal tissue 
injury (Fig. 1)
14). Non-traditional mediators of ARVD such as 
inflammatory pathways, reactive oxygen species production, 
ischemia/reperfusion damage and modulation of matrix turnover 
have been proposed as causes of the renal failure related to ARVD
15). 
This complexity of the pathophysiology might explain why the 
severity of the stenosis is not correlated with renal dysfunction. 
Clinical data support dissociation of improved renal artery 
patency from clinical outcome in patients with atherosclerotic 
renal artery stenosis; this may illustrate the effects of irreversible 
injury on the post stenotic kidney. A prospective clinical study 
reported by Wright et al. showed absence of a correlation between 
renal artery anatomy and baseline renal function or functional 
outcome, and a good correlation between renal functional outcome 
and proteinuria; these findings suggest that renal parenchymal 
damage is a major determinant of renal dysfunction and outcome 
rather than the severity of the renal artery stenosis in ARVD
16). 
Radermacher et al. reported that the mean arterial pressure did not 
decrease by 10 mmHg or more after revascularization and renal 
function declined in most patients with ARVD that had high 
resistance-index values before revascularization
17). Chrysochou et 
al. showed a correlation between baseline proteinuria and decline 
in estimated glomerular filtration rate (GFR) with time after 
revascularization
18). Therefore, post stenotic renal injury can lead 
to renal parenchymal injury reflected by high intrarenal resistance 
and/or the presence of proteinuria. Proteinuria and other factors 
involved in intrarenal resistance are predictors of a poor outcome 
after renal revascularization in ARVD.
When patients with chronic kidney disease undergo renal 
angioplasty with/without stent placement, the response with 
regard to renal function can be negative as well as positive. Posi-
tive responses include improvement of renal function, and 
stabilization or attenuation of declining renal function, as expected. 
However, sometimes declining renal function is accelerated after 
revascularization. Possible causes of these adverse outcomes include 
contrast induced nephropathy, atheroembolism, and restenosis or 
stent thrombosis
19). The administration of contrast might increase 
the risk of acute renal dysfunction, especially in patients that have 
preexisting renal impairment. An ex vivo study reported that each 
manipulation of atheroma specimens, from simply advancing the 
guidewire through the atherosclerotic lesion to positioning and 
deploying the Wallstent, releases thousands of fragments, and 
that these atherosclerotic fragments are of sufficient size to create 
vascular occlusion and initiate significant renal parenchymal 
damage
20). Currently, there is no way to predict positive or negative 
responses after revascularization. 
Factors favoring medical therapy
ARVD is a cardiovascular condition that is associated with 
renal artery stenosis. The nature of this disorder suggests that a 
systemic approach is necessary to provide cardiovascular protection. 
Previously, statin therapy was discussed as a method of altering 
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Fig. 1. Mechanisms of Renal Damage Associated with Atherosclerotic 
Renal Artery Stenosis. These mechanisms include an interaction among 
increased oxidative stress, immune responses, inflammation, immune 
responses, and angiotensin II/endothelin, which impair renal function, 
induce endothelial and epithelial dysfunction and injury, and may 
lead to irreversible scarring. Ox LDL, oxidized low-density lipoprotein 
cholesterol.
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the natural history of ARVD
11). Angiotensin-converting enzyme 
inhibitors and angiotensin receptor blockers effectively reduce 
blood pressure in patients with renovascular disease. In addition, a 
population-based cohort study of over 3,500 patients with ARVD 
in Canada found that angiotensin inhibitors could cause acute 
renal toxicity in a small subset of vulnerable patients; however, they 
still improved the cardiovascular and renal outcomes in patients 
with ARVD, but at the expense of acute renal toxicity
21).
Recently three randomized controlled trials have been 
performed: the Stent Placement and Blood Pressure and Lipid-
lowering for the Prevention of Progression of Renal Dysfunction 
Caused by Atherosclerotic Ostial Stenosis of the Renal Artery 
(STAR) trial, the Angioplasty and Stenting for Renal Artery 
Lesions (ASTRAL) trial, and the Cardiovascular Outcomes in 
Renal Artherosclerotic Lesions (CORAL) trial (Table 1). Two 
large randomized trials of intervention vs. medical therapy showed 
negative results for the intervention. The last trial is under way. 
The STAR trial was a European multicenter trial that enrolled 140 
patients with ostial renal artery stenosis greater than 50%, blood 
pressure controlled to less than 140/90 mmHg, and creatinine 
clearance 15 to 80 mL/min
7). All patients received angiotensin 
blocking agents and a statin, regardless of their lipid levels. After 
a 2-year interventional period, no difference was observed in the 
decline of renal function, the degree of blood pressure control, and 
the rates of cardiovascular morbidity and death. Investigators in 
the ASTRAL trial enrolled 806 patients with at least one stenotic 
renal artery considered suitable for balloon angioplasty, stenting, or 
both in their international, multicenter trial
8). The mean estimated 
GFR was 40 mL/min, and most of the patients were on statin and 
angiotensin blocking therapy. At a mean follow-up of 33.6 months, 
no difference was noted between the treatment groups in the 
decline of renal function or blood pressure control, and the renal 
function worsened slightly in both groups. Most of the enrolled 
patients in the two clinical trials had relatively asymptomatic 
atherosclerotic renal artery stenosis. Therefore, the practice of 
indiscriminately performing revascularization, without strong 
evidence, is no longer acceptable. The CORAL trial is an ongoing 
multicenter randomized controlled trial in the United States
22). It 
is still enrolling patients that have drug-resistant hypertension or 
a GFR < 60 mL/min. It is using a standardized medical protocol 
to control blood pressure, and embolic protection devices during 
procedures are encouraged. 
Thus far, intervention has not been recommended if renal 
function has remained stable over the past 6 to 12 months and 
if hypertension can be controlled medically. According to a 
clinical classification of atherosclerotic renal artery stenosis with 
guidelines for vascular intervention of surveillance published in 
2008 by the Atherosclerotic Peripheral Vascular Symposium
23), 
additional recommendations favoring medical therapy were as 
follows: very advanced age and/or limited life expectancy, extensive 
co-morbidities that make revascularization too risky, high risk 
for or previous experience with atheroembolic disease, and other 
concomitant renal parenchymal diseases that cause progressive renal 
dysfunction (e.g., interstitial nephritis, diabetic nephropathy)
23). 
Table 1. Recent Three Randomized Controlled Trials in Patients with Atherosclerotic Renal Artery Stenosis
Trial  Main selection criteria
Treatment group 
(n)
Control group 
(n)
Primary outcome Results
Intervention-related 
complications (%)
STAR
7) 
ASTRAL
8)
CORAL
22)
Stenosis ≥ 50%
GFR 15–80 mL/min
Stable BP
Stenosis with no 
clear indication of 
revascularization
Stenosis ≥ 60%
Systolic BP ≥ 155 
mmHg on ≥ 2 anti-
hypertension drugs
PTA plus stent 
(64) 
PTA with or 
without stent 
(403)
PTA plus stent 
Medication (76)
Medication (403)
Medication 
Decrease in GFR ≥ 20%
Reciprocal creatinine level 
over time
Doubling of serum creatinine
Need for renal replacement 
therapy
No significant difference in 
primary outcome or BP
 
No significant difference 
in primary outcome, 
BPand cardiovascular 
events
On-going
Death (3.2)
Hematomas (17)
Acute kidney injury (8)
Death (0.7)
Hospitalization for 
hematomas (1.4)
Acute kidney injury (2.1)
STAR, Stenosis of the Renal Rrtery; ASTRAL, Angioplasty and Stenting for Renal Artery Lesions; CORAL, Cardiovascular Outcomes in Renal 
Artherosclerotic Lesions; GFR, glomerular filtration rate; BP, blood pressure; PTA, percutaneous transluminal angioplasty.90      W Chung et al. • Atherosclerotic Renovascular Hypertension
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They also recommended factors favoring medical therapy and 
intervention as follows: progressive decline in GFR during 
treatment of systemic hypertension, failure to achieve adequate 
blood pressure control with optimal medical therapy (medical 
failure), rapid or recurrent decline in the GFR in association with a 
reduction in systemic pressure, decline in the GFR during therapy 
with angiotensin-converting enzyme inhibitors or angiotensin 
receptor blockers, and recurrent congestive heart failure in a patient 
in whom the adequacy of left ventricular function does not provide 
an explanation
23). The best evidence supporting intervention is for 
bilateral stenosis with “flash” pulmonary edema, but the evidence is 
from retrospective studies
24-26). 
Conclusion
The aim of treatment for ARVD should include the prevention 
of cardiovascular and/or renal events. Treatment of patients with 
ARVD should include consideration of the following factors: age, 
co-morbidity, blood pressure, renal function, and kidney size. The 
results of two recent studies suggest that patients with ARVD and 
stable renal function can be controlled medically. Intervention 
should be considered only in patients with ARVD and rapidly 
progressive cardiac or renal dysfunction. However, these conditions 
also increase the risk of complications related to revascularization 
procedures. Both the risks and potential long-term benefits of 
intervention should be considered. The results of the CORAL 
and the post hoc analysis of ASTRAL might provide additional 
evidence for revascularization.
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